Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Gross Profit (2018 - 2025)

Sunshine Biopharma's Gross Profit history spans 8 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 2.08% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $12.3 million, up 14.86%, while the annual FY2025 figure was $12.3 million, 14.86% up from the prior year.
  • Gross Profit reached $3.0 million in Q4 2025 per SBFM's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $3.4 million in Q2 2025 to a low of $21538.0 in Q1 2021.
  • Average Gross Profit over 5 years is $1.7 million, with a median of $2.0 million recorded in 2023.
  • Peak YoY movement for Gross Profit: surged 6157.61% in 2022, then decreased 2.08% in 2025.
  • A 5-year view of Gross Profit shows it stood at $23829.0 in 2021, then soared by 6157.61% to $1.5 million in 2022, then soared by 72.22% to $2.6 million in 2023, then grew by 20.44% to $3.1 million in 2024, then dropped by 2.08% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Gross Profit are $3.0 million (Q4 2025), $3.1 million (Q3 2025), and $3.4 million (Q2 2025).